|
2. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitusSabina Semiz, Tanja Dujić, Barbara Ostanek, Besim Prnjavorac, Tamer Bego, Maja Malenica, Janja Marc, Adlija Čaušević, 2010, original scientific article Keywords: CYP2C9, farmakogenetika, CYP2C19, CP2D6, diabetes Full text (outside link) |
|
4. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and HerzegovinaSabina Semiz, Tanja Dujić, Barbara Ostanek, Besim Prnjavorac, T. Bego, M. Malenica, Barbara Mlinar, Janja Marc, A. Čaušević, 2011, original scientific article Keywords: citokrom P450, CYP3A4, CYP3A5, farmakogenetika Full text (outside link) |
5. Association of NAT2 polymorphisms with type 2 diabetes in a population from Bosnia and HerzegovinaSabina Semiz, Tanja Dujić, Barbara Ostanek, Zelija Velija-Asimi, Besim Prnjavorac, T. Bego, M. Malenica, Barbara Mlinar, Bećir Heljić, Janja Marc, A. Čaušević, 2011, original scientific article Keywords: N-acetiltransferaza, diabetes tipa 2, polimorfizem, NAT2*5, NAT2*6 Full text (outside link) |
6. PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: A pilot studyJana Dragojevič, Barbara Ostanek, Simona Mencej Bedrač, Radko Komadina, Janez Preželj, Janja Marc, 2011, original scientific article Keywords: osteoporoza, RANKL, genetika, mineralna kostna gostota Full text (outside link) |
7. Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatmentTina Trdan Lušin, Aleš Mrhar, Bruno Stieger, Gerd A. Kullak-Ublick, Janja Marc, Barbara Ostanek, Andrej Zavratnik, Albin Kristl, Katja Berginc, Katja Delić, Jurij Trontelj, 2012, original scientific article Keywords: raloksifen, osteoporoza, zdravljenje, farmakokinetika, farmakodinamika Full text (outside link) |
|
|
|